Emergent BioSolutions to Acquire Adapt Pharma with Narcan (naloxone HCl) Nasal Spray

 Emergent BioSolutions to Acquire Adapt Pharma with Narcan (naloxone HCl) Nasal Spray

Emergent BioSolutions to Acquire Adapt Pharma with Narcan (naloxone HCl) Nasal Spray

Shots: 
  • Emergent will acquire Adapt with its leading product Narcan, approved by the FDA and Health Canada for the treatment of known or suspected opioid overdose       
  •  Under the agreement, Adapt will receive total up to $735M, including $635M upfront ($575M cash + $60M Emergent common stock), additionally $100M sales milestone payments on till 2022
  • The acquisition is expected to bring increment in revenue $200 to 220M and EBITDA in 2019, expected acquisition completion in Q4’18
Click here to read full press release/ article | Ref: Emergent BioSolutions  | Image: Emergency services

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post